In a recent report, Oppenheimer has raised the EPS estimate on Arena Pharmaceuticals ARNA from $0.58 to $0.69 and continues to see obstacles for the Lorcasserin approval.
In the report, Oppenheimer said, "ARNA plans to conduct 3 mo. preclinical trials to resolve this key issue, notably, however, the FDA suggested 12 mo. trials may be necessary. Given significant uncertainty surrounding lorcaserin's path to approval, and few catalysts, we see limited near-term upside for ARNA."
Arena Pharmaceuticals closed yesterday at $1.35.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in